Encysive Hits Another Snag With Thelin
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests the company reformat information included in its response to a second “approvable” letter.
You may also be interested in...
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.